The ABCs of ADCs: Why antibody-drug conjugates are so hot right now

from BioSpace · host BioSpace

These days you can hardly move without figuratively bumping into antibody-drug conjugates (ADCs). This week we discuss Pfizer's strategic priorities for oncology - focused on ADCs and less on small molecules - and how the market is being influenced by the IRA.

Episode metadata supplied by the publisher feed · Published Mar 6, 2024

Embed this episode

Attribution link and audio player

NOW PLAYING

The ABCs of ADCs: Why antibody-drug conjugates are so hot right now

0:00 11:06

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of BioSpace?

This episode is 11 minutes long.

When was this BioSpace episode published?

This episode was published on March 6, 2024.

Can I download this BioSpace episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!